Clinical evaluation of dried blood spots for the determination of ribociclib blood levels

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON25336

Enrollment

Registered

2019-11-25

Start date

2019-09-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced breast cancer

Interventions

Patients are treated with ribociclib on a dose according to the prescription of the physician. A DBS sample will be obtained simultaneously with a regular plasma sample on a maximum of 4 different reg

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age = 18 years; 2. Able to understand the written information and able to give informed consent; 3. Treated with ribociclib; 4. Able and willing to undergo a finger prick for dried blood spot sampling.

Exclusion criteria

Exclusion criteria: 1. Unable to draw blood for study purposes.

Design outcomes

Primary

Measure	Time frame
The main study parameter is the agreement between ribociclib plasma levels of blood collected by venipuncture or DBS.	—

Contacts

Public ContactCornelis Louwrens, PharmD Braal

Erasmus MC Cancer Institute

c.braal@erasmusmc.nl06-18197784

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)